Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Elicio TherapeuticsELTX +0.01%26 3-Year Share Buyback Ratio is -26.80 as of Jun. 2026. GuruFocus rates ELTX with a GF Score™ of 26/100. Among 1,184 Biotechnology companies, Elicio Therapeutics ranks worse than 71.37% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Elicio Therapeutics's current 3-Year Share Buyback Ratio was -26.80%.
The historical rank and industry rank for Elicio Therapeutics's 3-Year Share Buyback Ratio or its related term are showing as below:
ELTX'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -26.8 Med: -2.5 Max: 0
Current: -26.8
During the past 10 years, Elicio Therapeutics's highest 3-Year Share Buyback Ratio was 0.00%. The lowest was -26.80%. And the median was -2.50%.
ELTX's 3-Year Share Buyback Ratio is ranked worse than 71.37% of 1184
companies
in the Biotechnology industry
Industry Median: -11.6
vs ELTX: -26.80
Elicio Therapeutics (NAS:ELTX) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Elicio Therapeutics 3-Year Share Buyback Ratio Related Terms
ELTX vs LONA, RNXT, NRXS: 3-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Elicio Therapeutics's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elicio Therapeutics 3-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Elicio Therapeutics's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Elicio Therapeutics's 3-Year Share Buyback Ratio falls into.
Elicio Therapeutics 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -26.80 mean?
Elicio Therapeutics (ELTX) has a 3-Year Share Buyback Ratio of -26.80 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Elicio Therapeutics and its competitors. According to the industry distribution chart, Elicio Therapeutics ranks #845 out of 1184 companies in the Biotechnology industry, placing it in the top 71.4%.
Is Elicio Therapeutics' 3-Year Share Buyback Ratio too high?
Elicio Therapeutics' current 3-Year Share Buyback Ratio is -26.80. Based on the distribution chart, Elicio Therapeutics ranks #845 out of 1184 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Elicio Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Elicio Therapeutics' 3-Year Share Buyback Ratio compare to LONA and RNXT?
According to the Biotechnology industry distribution chart, Elicio Therapeutics ranks #845 out of 1184 companies for 3-Year Share Buyback Ratio. This places Elicio Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Elicio Therapeutics and its competitors. Elicio Therapeutics's current 3-Year Share Buyback Ratio is -26.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elicio Therapeutics stock overvalued right now?
Elicio Therapeutics (ELTX) has a current 3-Year Share Buyback Ratio of -26.80. The current 3-Year Share Buyback Ratio is -26.80. Elicio Therapeutics' overall GF Score™ is 26/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Elicio Therapeutics (ELTX), the current 3-Year Share Buyback Ratio is -26.80 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
26GF Score
Get the complete analysis for ELTX
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELTX has been successfully added to your 
